HLA-DRB1*16:01 and HLA-DQB1*05:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma.

BACKGROUND: The influence of HLA class I and II loci on the susceptibility to melanoma remains an area of intense debate. This study aimed to examine whether the HLA system was related to melanoma susceptibility and prognosis in a southern Spanish population. METHODS: In this study, HLA class I and...

ver descrição completa

Detalhes bibliográficos
Autores: Wang X, Almazan F, Montoyo-Pujol YG, Martin-Casares A, Martin A, Cabrera T, López-Nevot MA
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2021
País:España
Recursos:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
Repositório:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
OAI Identifier:oai:isabial.fundanetsuite.com:p8812
Acesso em linha:https://isabial.portalinvestigacion.com/publicaciones8812
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497119/
Access Level:Acceso aberto
id ES_f686a9a1dbddcd74d18397f03319f8b2
oai_identifier_str oai:isabial.fundanetsuite.com:p8812
network_acronym_str ES
network_name_str España
repository_id_str
spelling HLA-DRB1*16:01 and HLA-DQB1*05:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma.Wang XAlmazan FMontoyo-Pujol YGMartin-Casares AMartin ACabrera TLópez-Nevot MABACKGROUND: The influence of HLA class I and II loci on the susceptibility to melanoma remains an area of intense debate. This study aimed to examine whether the HLA system was related to melanoma susceptibility and prognosis in a southern Spanish population. METHODS: In this study, HLA class I and class II genotyping were performed using polymerase chain reaction sequence-specific oligonucleotides (PCR-SSO) in 237 Spanish melanoma patients and 636 ethnically matched controls. Data were analyzed according to the clinical characteristics of the defined subgroups. RESULTS: Compared to the control group, DRB1*16:01 (4% vs. 1.3%, p=0.001, Pc = 0.035, OR = 3.28) and DQB1*05:02 (4.9% vs. 2%, p=0.001, Pc = 0.017, OR = 2.54) were positivity associated with the susceptibility to melanoma. Both DRB1*16:01 (5.4% vs. 1.3%, p=0.001, Pc = 0.035, OR = 4.46) and DQB1*05:02 (6.5% vs. 2%, p=0.001, Pc = 0.017, OR = 3.44) also showed a positive correlation with Breslow thickness >1.5 mm, most notably at an early age of diagnosis (=58 years), DRB1*16:01 (4.2% vs. 1.3%, p=0.001, Pc = 0.035, OR = 3.41) and DQB1*05:02 (5.4% vs. 2%, p=0.002, Pc = 0.034, OR = 2.86). CONCLUSION: These findings established HLA-DRB1*16:01 and HLA-DQB1*05:02 loci as melanoma risk factors in the southern Spanish population.HINDAWI LTD2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://isabial.portalinvestigacion.com/publicaciones8812https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497119/Journal of OncologyISSN: 16878450ISSNe: 16878469reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicanteinstname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)Inglésinfo:eu-repo/semantics/openAccessoai:isabial.fundanetsuite.com:p88122026-06-12T10:20:37Z
dc.title.none.fl_str_mv HLA-DRB1*16:01 and HLA-DQB1*05:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma.
title HLA-DRB1*16:01 and HLA-DQB1*05:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma.
spellingShingle HLA-DRB1*16:01 and HLA-DQB1*05:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma.
Wang X
title_short HLA-DRB1*16:01 and HLA-DQB1*05:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma.
title_full HLA-DRB1*16:01 and HLA-DQB1*05:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma.
title_fullStr HLA-DRB1*16:01 and HLA-DQB1*05:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma.
title_full_unstemmed HLA-DRB1*16:01 and HLA-DQB1*05:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma.
title_sort HLA-DRB1*16:01 and HLA-DQB1*05:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma.
dc.creator.none.fl_str_mv Wang X
Almazan F
Montoyo-Pujol YG
Martin-Casares A
Martin A
Cabrera T
López-Nevot MA
author Wang X
author_facet Wang X
Almazan F
Montoyo-Pujol YG
Martin-Casares A
Martin A
Cabrera T
López-Nevot MA
author_role author
author2 Almazan F
Montoyo-Pujol YG
Martin-Casares A
Martin A
Cabrera T
López-Nevot MA
author2_role author
author
author
author
author
author
description BACKGROUND: The influence of HLA class I and II loci on the susceptibility to melanoma remains an area of intense debate. This study aimed to examine whether the HLA system was related to melanoma susceptibility and prognosis in a southern Spanish population. METHODS: In this study, HLA class I and class II genotyping were performed using polymerase chain reaction sequence-specific oligonucleotides (PCR-SSO) in 237 Spanish melanoma patients and 636 ethnically matched controls. Data were analyzed according to the clinical characteristics of the defined subgroups. RESULTS: Compared to the control group, DRB1*16:01 (4% vs. 1.3%, p=0.001, Pc = 0.035, OR = 3.28) and DQB1*05:02 (4.9% vs. 2%, p=0.001, Pc = 0.017, OR = 2.54) were positivity associated with the susceptibility to melanoma. Both DRB1*16:01 (5.4% vs. 1.3%, p=0.001, Pc = 0.035, OR = 4.46) and DQB1*05:02 (6.5% vs. 2%, p=0.001, Pc = 0.017, OR = 3.44) also showed a positive correlation with Breslow thickness >1.5 mm, most notably at an early age of diagnosis (=58 years), DRB1*16:01 (4.2% vs. 1.3%, p=0.001, Pc = 0.035, OR = 3.41) and DQB1*05:02 (5.4% vs. 2%, p=0.002, Pc = 0.034, OR = 2.86). CONCLUSION: These findings established HLA-DRB1*16:01 and HLA-DQB1*05:02 loci as melanoma risk factors in the southern Spanish population.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://isabial.portalinvestigacion.com/publicaciones8812
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497119/
url https://isabial.portalinvestigacion.com/publicaciones8812
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497119/
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv HINDAWI LTD
publisher.none.fl_str_mv HINDAWI LTD
dc.source.none.fl_str_mv Journal of Oncology
ISSN: 16878450
ISSNe: 16878469
reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
instname_str Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
reponame_str r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
collection r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424771042639872
score 15,812429

Registros relacionados